Compare BridgeBio Pharma Inc (BBIO) vs Coupang Inc (CPNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Coupang Inc — how do they compare? BridgeBio Pharma Inc trades at $84.69 (market cap $16.36B), while Coupang Inc trades at $16.52 (market cap $29.66B). The key difference: Coupang Inc is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Coupang Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | CPNG | |
|---|---|---|
Market Cap | $16.36B | $29.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $33.53 |
52-Week Low | $47.29 | $15.12 |
Enterprise Value | $18.14B | $29.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.57, down slightly by 0.12% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth driven by Attruby sales, though it missed EPS estimates. With a high P/S ratio of 22.77 and negative profitability metrics, the stock is priced for future growth, supported by strong analyst buy ratings and a $104.56 consensus price target.
The outlook hinges on successful product launches and regulatory approvals, with three potential launches expected within 12 months offering significant upside. Key risks include persistent cash burn, high debt, and execution challenges in bringing new treatments to market, which could pressure the stock if milestones are missed.
CPNG trades at $16.55, up 2.22% today, with a neutral technical signal and bearish moving averages. Revenue grew to $34.53B in 2025, but recent quarters missed EPS expectations, and 2026 projects a net loss. The stock is undervalued relative to analyst consensus targets near $23.38, supported by strong cash flow from operations of $1.77B in 2025.
Outlook remains mixed due to near-term profitability challenges, but long-term growth in South Korean e-commerce and expansion into Taiwan offer upside. Risks include competitive pressures, regulatory fines, and execution on margin improvement. Analyst sentiment is overwhelmingly bullish with 87.5% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →
